Last update 21 Nov 2024

Bacampicillin Hydrochloride

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1'-ethoxycarbonyloxyethyl-(6-D-α-aminophenylacetamido)penicillanate, 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate, Bacampicillin

+ [6]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases+ [7]

Active Indication

Acute BronchitisAdnexitisBurns+ [25]

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.Astra Lakemedel AB

Inactive Organization

Pfizer Laboratories (Pty) Ltd.

Drug Highest PhaseApproved

First Approval Date

US (22 Dec 1980),

GonorrheaRespiratory Tract InfectionsUrinary Tract Infections

Regulation-

Structure

Molecular FormulaC21H27N3O7S

InChIKeyPFOLLRNADZZWEX-FFGRCDKISA-N

CAS Registry50972-17-3

View All Structures (2)

100 Clinical Results associated with Bacampicillin Hydrochloride

100 Translational Medicine associated with Bacampicillin Hydrochloride

100 Patents (Medical) associated with Bacampicillin Hydrochloride

226

Literatures (Medical) associated with Bacampicillin Hydrochloride

01 Nov 2016·International Journal of Infectious DiseasesQ3 · MEDICINE

Antimicrobial drug use in primary healthcare clinics: a retrospective evaluation

Q3 · MEDICINE

ArticleOA

Author: Muhammad Eid Akkawi ; Mohamed Mansor Manan ; Long Chiau Ming ; Shafinaz Shamsuddin ; Syed Tabish Razi Zaidi

OBJECTIVESTo examine the appropriateness of antibiotics prescribed for acute infection based on the Malaysian national antibiotic guidelines and the defined daily dose (DDD) system of the World Health Organization (WHO). This study also aimed to describe the factors influencing the drug use pattern and to investigate the procurement patterns of antibiotics in the primary healthcare setting.METHODSA retrospective cohort follow-up study of randomly selected patients from all patients who received any antibiotic between January and December 2013 was conducted at three primary healthcare clinics in Selangor State of Malaysia. For each patient, the following information was recorded: name of the antibiotic, frequency and dose, and Anatomical Therapeutic Chemical (ATC) group. The defined daily dose per 1000 inhabitants per day was calculated for each antibiotic. The national antibiotic guidelines were used to assess the appropriateness of each antibiotic prescription.RESULTSA total of 735 patients were included in the study. The five most used antibiotics were amoxicillin (1.36g, 35.2%), cloxacillin (0.68g, 26.3%), erythromycin (0.32g, 22.3%), bacampicillin (0.13g, 7.2%), and cephalexin (0.11g, 6.9%). Respiratory tract infections were the most commonly treated infections, and the doctors' preferred antibiotic for the treatment of these infections was amoxicillin. More than 18% of all amoxicillin prescriptions were deemed inappropriate according to the national antibiotic guidelines. In terms of procurement costs, USD 88885 was spent in 2011, USD 219402 in 2012, and USD 233034 in 2013 at the three primary healthcare clinics, an average of USD 180440 per year for the three clinics.CONCLUSIONSThis study reports the antibiotic usage at three primary healthcare clinics in Klang Province. The most prescribed antibiotic was amoxicillin in capsules (250mg), which was mainly prescribed for respiratory infections. Although the national antibiotic guidelines state that amoxicillin is a preferred drug for acute bacterial rhinosinusitis, this drug is also being prescribed for other disease conditions, such as acute pharyngitis and acute tonsillitis. This result shows that current practice is not following the current antibiotic guidelines, which state that phenoxypenicillin should be the preferred drug.

01 Jan 2011·International Archives of Allergy and ImmunologyQ3 · MEDICINE

Tolerability of Aztreonam in Patients with Cell-Mediated Allergy to β-Lactams

Q3 · MEDICINE

Article

Author: Colagiovanni, A. ; Patriarca, G. ; Nucera, E. ; Pecora, V. ; Lombardo, C. ; Aruanno, A. ; De Pasquale, T. ; Buonomo, A. ; Rizzi, A. ; Pascolini, L. ; Sabato, V. ; Schiavino, D.

Background: Cross-reactivity between aztreonam and β-lactams is poor, but tolerability of aztreonam has been assessed in a few groups of patients suffering from IgE-mediated allergy to β-lactams. The aim of this study was to assess the cross-reactivity of aztreonam with other β-lactams and its tolerability in patients with cell-mediated allergy to these drugs. Methods: We studied 78 patients with cell-mediated allergy to β-lactams who underwent skin prick, immediate and delayed-reading intradermal tests as well as patch tests with penicilloyl-polylysine, minor determinant mixture, semi-synthetic penicillins, cephalosporins, aztreonam and imipenem. Patients with negative allergy testing with aztreonam underwent an intramuscular test dosing and were observed for 3 h. Results: Our patients experienced 94 non-immediate reactions; delayed-onset urticaria (34 cases), maculopapular exanthema (13 cases), urticaria/angioedema (15 cases) and itching erythema (13 cases) were the most reported symptoms. Amoxicillin (35 cases), ampicillin (28 cases) and bacampicillin (18 cases) were the most involved drugs. All patients had a positive patch test and/or a positive delayed-reading intradermal test to at least 1 β-lactam antibiotic and none had a positive patch or delayed-reading intradermal test to aztreonam. Then, 65 patients underwent intramuscular test dosing with aztroenam, and none of them had a clinical reaction. Conclusions: Our data confirm the lack of cross-reactivity between β-lactams and aztreonam in patients with cell-mediated allergy to these drugs. Delayed-reading intradermal tests and patch tests with aztreonam represent a simple and rapid diagnostic tool to establish tolerability in β-lactam-allergic patients.

01 Jan 2007·Biological and Pharmaceutical BulletinQ4 · MEDICINE

Bacampicillin Uptake Is Shared with Thiamine in Caco-2 Cells

Q4 · MEDICINE

Article

Author: Fujimoto, Kaori ; Oda, Masako ; Kobayashi, Michiya ; Saitoh, Hiroshi

Bacampicillin was developed as a prodrug to improve the intestinal absorption of its metabolite ampicillin. This study was undertaken to characterize bacampicillin transport in Caco-2 cells. The uptake of bacampicillin in Caco-2 cells was significantly greater than those of ampicillin and pivampicillin. An Eadie-Hofstee plot obtained from 5-min uptake of 0.2-5 mM bacampicillin was linear, indicating the presence of a saturable transport system for bacampicillin with K(m) and V(max) of 3.6 mM and 23.9 nmol/mg protein/min, respectively. Hydrophilic organic cations such as choline, cimetidine, guanidine, nicotinamide, 1-methylnicotiamide, and tetraethylammonium failed to modulate bacampicillin uptake in Caco-2 cells whereas diphenhydramine, procainamide, and thiamine significantly depressed it. Moreover, when thiamine was preloaded in Caco-2 cells, bacampicillin uptake was significantly increased, indicating that this cationic vitamin was capable of trans-stimulating bacampicillin transport across the apical membrane of Caco-2 cells. However, trans-stimulated bacampicillin uptake was not observed in the presence of diphenhydramine. Bacampicillin uptake increased with elevation of the medium pH, and the known modulators of thiamine transport such as amiloride and oxythiamine significantly inhibited bacampicillin uptake. Thiamine also significantly decreased the apical-to-basolateral transport of bacampicillin across Caco-2 cell monolayers. However, thiamine did not exert any modulating effect on pivampicillin uptake and its apical-to-basolateral permeation in Caco-2 cells. These results suggest that bacampicillin is transported in Caco-2 cells, sharing a carrier-mediated system with thiamine.

100 Deals associated with Bacampicillin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00927	Bacampicillin Hydrochloride	J01CA06	DB01602

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Bronchitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Adnexitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Cystitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Hordeolum	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Intrauterine infection	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Keratitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Laryngitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Lymphangitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Mastitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Non-complicated skin and skin structure infection	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Otitis Media	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pericoronitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Peritonitis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pneumonia	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pyelonephritis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pyoderma	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Scarlet Fever	JP	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Respiratory Tract Infections	CN	Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.	01 Jan 1993
Soft Tissue Infections	CN	Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.	01 Jan 1993
Urinary Tract Infections	CN	Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.	01 Jan 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	Preclinical	SE	Astra Lakemedel AB	01 Nov 1975

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis